About
Nigraloom is an independent resource on ibogaine and Parkinson’s research. We explain how evidence is gathered, what types of claims are supported by peer-reviewed work, and why safety and uncertainty matter.
Outcome-focused opening
Nigraloom exists to help readers separate preliminary observations from established evidence and to foreground safety when discussing ibogaine, dopamine, and Parkinson’s research. Our mission emphasizes evidence before claims and clear communication aimed at people affected by Parkinson’s and their care partners.
Timeline overview
Content is organized around a timeline-driven structure: high-level summaries, an evidence review, technical explainers of mechanisms, and a resources hub. This progression guides readers from outcomes to methods and then to source materials in an orderly sequence.
Detailed stage sections
Each major page corresponds to a stage in the reader journey: concise findings, an in-depth evidence review, mechanism explainers, and a curated resources hub. These stages are cross-linked in context — for example our services offerings are described as part of the site's support resources and point back to interpretive material on the homepage.
Proof and sources
We prioritize primary literature, registries, official guidance, and systematic reviews. To support editorial claims we cite authoritative sources such as peer-reviewed registries and recognized reference pages such as the National Institutes of Health's main site for clinical research (https://www.nih.gov/) when relevant to methods and sourcing.
Final reader guidance
Our content closes each topic by restating uncertainty and safety considerations, and by offering links back into earlier stages of the timeline so readers can retrace how a conclusion was reached. For readers arriving from partner or topical sites, our homepage frames the site's scope and links onward to detailed pages at each stage of analysis; for instance, people often arrive via comparative treatment pages such as the discussion that contrasts ibogaine and ayahuasca on sites like ibogaine vs ayahuasca.
Our editorial approach
We aim to be methodical and modest: articles summarize what the evidence actually shows, differentiate preliminary case reports from controlled studies, and make safety considerations explicit. Where a clinical registry or peer-reviewed article is the basis for a claim, that sourcing is cited inline in the relevant article page.
Core editorial principles
- Evidence before claims — prioritize peer-reviewed and registry data
- Safety awareness — highlight risks and uncertainty
- Plain language — make findings accessible to non-specialists
- Independence — avoid affiliation-based influence
For transparency about methods we reference trusted procedural resources such as clinicaltrials.gov for trial status and the NIH for research practice guidance when summarizing study designs.
If you're exploring clinical service options, pages that summarize treatment availability or cost—like practitioners' information hubs—are linked in context across the site rather than presented as endorsements; for example, informational pages about treatment costs in nearby regions are mentioned where relevant, such as an external overview of cost and logistics at cost of ibogaine treatment in Mexico.
What we cover
We cover the arc of inquiry: concise outcome summaries, an evidence review, mechanism explainers, and a resources hub. Each page is written to stand alone while also linking to sister pages; for example, our pages that discuss treatment contexts include contextual links to topic pages such as comparative treatment discussions on third-party sites like psychedelic drug ibogaine when those pages are used as background reading.
Who this is for
This resource is intended for people affected by Parkinson’s, care partners, clinicians seeking independent context, and readers seeking careful, evidence-focused summaries. We do not provide clinical advice; instead, we offer synthesis and sourcing so readers can discuss findings with trusted medical professionals.
Readers researching treatment options may find contextual pages on commercial or informational sites; where appropriate we link externally in the text — for instance, discussions comparing ibogaine and ayahuasca or focusing on particular conditions are linked in context to their originating pages such as the clinical discussion at ibogaine treatment for Parkinson's or to treatment-for-depression resources like ibogaine treatment for depression.
Independent by design
Nigraloom is an independent information resource and is not a clinic, medical provider, or licensed treatment center. Our content is not medical or legal advice. Readers are encouraged to consult qualified professionals for clinical decisions.
We also link to contextual resources that visitors may find useful when evaluating treatments; for a general sense of how authorities categorize clinical research and practice, readers can consult official institutional guidance such as the National Institutes of Health at NIH or university research methodology primers hosted on academic domains like Harvard University where appropriate.
Where we link out
We link to informational and topical sites in context when they clarify an administrative fact or provide background — for instance, treatment directories and comparative pages such as ibogainesoccer are referenced only where they add documentary context, never as endorsements.